相关实验视频

Updated: Jun 26, 2026

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

肺癌中的DNA甲基化:有效免疫治疗的预测生物标志物

Komal Kumari¹, Vinay Kumar², Chaitenya Verma³

¹Department of Biotechnology, Central University of South Bihar, Gaya, BR, 824236, India.

International journal of general medicine

|January 7, 2026

概括

DNA甲基化 (DNAm) 可以预测肺癌的免疫疗法反应. 本综述探讨了DNAm作为一种生物标志物,以提高治疗疗效和个性化策略,以获得更好的患者结果.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
免疫学免疫学免疫学

背景情况:

肺癌是全球癌症死亡的主要原因之一.
免疫疗法是有前途的,但它只对一小部分患者有益.
预测性生物标志物对于个性化肺癌治疗至关重要.

研究的目的:

审查DNA甲基化 (DNAm) 作为肺癌免疫治疗的预测生物标志物.
突出DNAm在免疫反应和治疗疗效中的作用.
讨论临床应用的综合表观遗传特征和液体活检.

主要方法:

关于DNA甲基化和肺癌免疫治疗的当前文献的综述.
分析免疫相关基因中的DNAm及其与瘤特征的关联.
对免疫疗法反应的既定和新兴生物标志物的评估.

主要成果:

DNA甲基化模式与瘤表型,免疫细胞透和对免疫检查点抑制剂 (ICI) 的反应相关.
DNAm作为一个关键的表观遗传生物标志物,用于预测免疫疗法的疗效.
综合表观遗传特征和液体活检显示出临床应用的潜力.

结论:

基因甲基化是个性化肺癌免疫疗法的关键表观遗传生物标志物.
需要进一步的研究来将表观遗传生物标志物转化为临床实践.
优化免疫治疗结果和减少不良事件是未来的关键方向.

关键词:

这是表观遗传生物标志物.免疫疗法免疫疗法微卫星的不稳定性瘤微环境是一个微环境.瘤突变负担的突变负担透到瘤中的淋巴细胞

更多相关视频

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.